title: Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus.
abstract: OBJECTIVE
  To investigate the prevalence of the anti-ribosomal P (anti-P) antibodies in childhood-onset systemic lupus erythematosus patients (cSLE), healthy controls and first degree relatives. To elucidate the association between anti-P and disease activity, laboratory and treatment features in cSLE patients.
  
  
  METHODS
  We included consecutive SLE patients with disease onset before 16 years. Controls were age- and sex-matched. SLE patients were assessed for clinical and laboratory SLE manifestations, disease activity (SLE Disease Activity Index (SLEDAI)), damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and current drug exposures. Mood disorders were determined through Becks Depression and Becks Anxiety Inventory. Anti-P measured by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  We included 50 consecutive cSLE patients (mean age of 16.82 ± 3.46 years), 35 first degree relatives (mean age of 38.73 ± 3.89 years) and 20 health control (mean age of 18.3 ± 4.97 years). Anti-P was observed in 13 (26%) cSLE patients and in no first-degree relative (p < 0.01) or control (p < 0.01). Anti-P was more frequently observed in patients with anxiety (p < 0.002). No other clinical, laboratory or treatment features, including SLEDAI and SDI scores were associated with the presence of anti-P in cSLE patients.
  
  
  CONCLUSIONS
  Anti-P is frequently observed in cSLE patients and was associated with the presence of anxiety in this cohort of cSLE.
authors: Department of Medicine, Rheumatology Unit, Faculty of Medical Science, State University of Campinas, Brazil.
authors: H
authors: H
authors: Aldar
authors: A T
authors: AT
authors: Lapa
authors: B
authors: B
authors: Bellini
authors: N A
authors: NA
authors: Sinicato
authors: M
authors: M
authors: Postal
authors: P T
authors: PT
authors: Fernandes
authors: L T L
authors: LT
authors: Costallat
authors: R
authors: R
authors: Marini
authors: S
authors: S
authors: Appenzeller
mesh_terms: D000293:Adolescent; D017668:Age of Onset; D001008:Anxiety Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D016022:Case-Control Studies; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005190:Family; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000503:physiopathology; D008297:Male; D019964:Mood Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology; D015995:Prevalence; D011569:Psychiatric Status Rating Scales; D012269:Ribosomal Proteins / Q000276:immunology*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D001323:Autoantibodies; D012269:Ribosomal Proteins